Global Oligonucleotide Therapeutics Market Size, Status and Forecast 2020-2026

SKU ID : QYR-15083380 | Publishing Date : 14-Jan-2020 | No. of pages : 97

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Market Analysis and Insights: Global Oligonucleotide Therapeutics Market
In 2019, the global Oligonucleotide Therapeutics market size was US$ 2670.1 million and it is expected to reach US$ 7961.1 million by the end of 2026, with a CAGR of 16.7% during 2021-2026.
Global Oligonucleotide Therapeutics Scope and Market Size
Oligonucleotide Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Oligonucleotide Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Oligonucleotide Therapeutics market is segmented into Antisense Oligonucleotide, Aptamer, Other, etc.
Segment by Application, the Oligonucleotide Therapeutics market is segmented into Neuromuscular Diseases, ATTR, Hepatic VOD, Other, etc.
Regional and Country-level Analysis
The Oligonucleotide Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Oligonucleotide Therapeutics market report are North America, Europe, South America, China and Japan, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and Oligonucleotide Therapeutics Market Share Analysis
Oligonucleotide Therapeutics market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Oligonucleotide Therapeutics business, the date to enter into the Oligonucleotide Therapeutics market, Oligonucleotide Therapeutics product introduction, recent developments, etc.
The major vendors include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics, etc.

This report focuses on the global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Oligonucleotide Therapeutics development in North America, Europe, South America, China and Japan.

The key players covered in this study

Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

Market segment by Type, the product can be split into

Antisense Oligonucleotide
In 2018, antisense oligonucleotides accounted for the highest proportion of income, reaching 96.52%.

Market segment by Application, split into

Neuromuscular Diseases
Hepatic VOD
According to the application, neuromuscular diseases and hepatic VOD are the most important, accounting for 51.69% and 42.23%, respectively.

Market segment by Regions/Countries, this report covers

North America
South America

The study objectives of this report are:

To analyze global Oligonucleotide Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Oligonucleotide Therapeutics development in North America, Europe, South America, China and Japan.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Oligonucleotide Therapeutics are as follows:
History Year: 2015-2019

Base Year:


Estimated Year:

Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions

This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
  • By product type
  • By End User/Applications
  • By Technology
  • By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
market Reports market Reports